CN103190619A - Fish oil and linseed oil soft capsules and preparation method thereof - Google Patents
Fish oil and linseed oil soft capsules and preparation method thereof Download PDFInfo
- Publication number
- CN103190619A CN103190619A CN2013101169046A CN201310116904A CN103190619A CN 103190619 A CN103190619 A CN 103190619A CN 2013101169046 A CN2013101169046 A CN 2013101169046A CN 201310116904 A CN201310116904 A CN 201310116904A CN 103190619 A CN103190619 A CN 103190619A
- Authority
- CN
- China
- Prior art keywords
- fish oil
- oil
- linseed oil
- soft capsule
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to fish oil and linseed oil soft capsules and a preparation method thereof. The soft capsules mainly comprise the following raw materials in parts by weight: 30 to 80 parts of fish oil, 20 to 60 parts of linseed oil, and 5 to 20 parts of vitamin E; and the fish oil and linseed oil soft capsules are prepared through the steps of preparing an inclusion, making capsule bodies, preparing capsules and the like. Compared with the prior art, the soft capsules have the advantages that the fish oil contains polyunsaturated fatty acids such as docosahexaenoic acid (DHA) and eicosapentanoic acid (EPA), so that low-density lipoprotein cholesterol in blood can be effectively reduced, the content of neutral fat is reduced, and high-density lipoprotein cholesterol is increased; and alpha-linolenic acid can promote the discharge of cholesterol, inhibit the synthesis of endogenous cholesterol and raise high-density lipoprotein, so that the effect of reducing blood fat is achieved.
Description
Technical field
The present invention relates to a kind of health food and preparation method thereof, especially relate to a kind of fish oil linseed oil soft capsule and preparation method thereof.
Background technology
In recent years, along with The development in society and economy, the change population of China blood lipid level of life style raises rapidly.It is the high risk factor that causes high blood pressure, diabetes, coronary heart disease, thrombotic diseases, gallstone disease, headstroke disease that dyslipidemia raises, seriously jeopardize the healthy of people, so my company intends the health care that a kind of health food expection of research and development reaches auxiliary antilipemic.
Discover that dietary fat acid plays an important role to blood lipid metabolism, polyunsaturated fatty acid has regulating action to blood fat, is conducive to reduce the blood fat of unusual rising and the risk factor that angiocardiopathy takes place.In recent years, the effect for reducing fat of polyunsaturated fatty acid more and more comes into one's own.
Phase early 1990s, the people of the U.S. about 60% surpasses the standard of marginality high fat of blood.Along with improving constantly of China's living standards of the people, the variation of dietary structure and life style, crowd's blood lipid level is raising generally year by year.The 8-12 month in 2002; the Ministry of Public Health, the Department of Science and Technology and State Statistics Bureau have organized each relevant departments of provinces, autonomous regions and municipalities in concert; carried out " Chinese residents nutrition and investigation of health conditions " in China; the survey showed that; China adult dyslipidemia illness rate is 18.6%, estimates that national dyslipidemia now suffers from number 1.6 hundred million.Dissimilar dyslipidemia now trouble number is respectively: hypercholesterolemia 2.9%, hypertriglyceridemia 11.9%, low hdl mass formed by blood stasis 7.4%.Other has people's cholesterolemia edge rising of 3.9%.It should be noted that a middle-aged person is close with the elderly's dyslipidemia illness rate, differentials between town and country are little.
Along with the number of dyslipidemia increases, demand to the lipopenicillinase series products is high, thereby more and more enterprises joins the production of fat-reducing medicament, from the whole world, fat regulation medicine growth rate in recent years remains on 25%～30%, the annual sales of fat regulation medicine in 2000 reaches 15,900,000,000 dollars, becomes world's second largest medicine classification.Calendar year 2001, transfer the blood fat product to reach 12～1,500,000,000 yuan in the total market size of China. hospital's prescription medication has occupied most shares, but health food has also therefrom extracted 1 hundred million sales volume.But the urgent consciousness that present China consumer does not transfer blood fat, often illness has occurred just can seeking medical advice purchasing medicine, transfers fat health products share extremely low.According to U.S.'s blood fat market status, transferring fat health products and fat regulation medicine product should be to have half share.Though the effect of fat-reducing medicament all exists multiple side effect: as the stimulating gastrointestinal road, cause abdominal distension and constipation than faster with obvious; Make the red swelling of the skin itch; The liver kidney is had damage etc., and the health food that therefore integrates the auxiliary antilipemic of nutrition and health care plays a very important role for improving the healthy tool of people.Therefore, along with the raising of China's living standards of the people and the reinforcement of health care consciousness, in the coming years, the sales volume of product also has largely and increases, and fat reducing health product should have bright development prospect.
Summary of the invention
Purpose of the present invention is exactly to provide a kind of can suppress that endogenous cholesterol is synthetic, increasing high density lipoprotein in order to overcome the defective that above-mentioned prior art exists, and reduces fish oil linseed oil soft capsule of blood fat and preparation method thereof.
Purpose of the present invention can be achieved through the following technical solutions:
A kind of fish oil linseed oil soft capsule, primary raw material comprises following component and weight portion content: fish oil 30-80, linseed oil 20-60, vitamin E 5-20.
Described fish oil is one or more in tunny fish oil or the cod oil.
EPA content is not less than 18wt% in the described fish oil, and DHA content is not less than 12wt%.
Linolenic acid content is 50wt% in the described linseed oil.
Fish oil linseed oil preparation of soft capsule method may further comprise the steps:
(1) preparation content: take by weighing fish oil, linseed oil, vitamin E by prescription, mix then and stir the content that obtained mixing in 30-60 minute;
(2) make utricule: be the utricule raw material with gelatin, glycerine and pure water, glycerine and pure water are injected in the glue pot, be heated with stirring to 60～70 ℃, add gelatin again, continue to stir final vacuum deaeration in 20-30 minute, make obtaining utricule;
(3) preparation capsule: content and step (2) making of step (1) preparation are obtained utricule process pelleting, finalize the design, wash ball, drying, choose ball and packing step, prepare the fish oil soft capsule.
The weight ratio of gelatin, glycerine, pure water is 10-20: 5-20: 1-10 in the step (2).
The temperature of the typing described in the step (3) is 18-30 ℃, and relative humidity is 30-60%, and shaping time is 4h.
Adopt the ethanol of 95wt% to wash the ball processing in the step (3).
The temperature of the drying described in the step (3) is 20-35 ℃, and be 8h drying time.
Every contains raw material 1000mg in the soft capsule that making obtains.
Compared with prior art, the present invention has the following advantages:
(1) contains DHA and EPA polybasic unsaturated fatty acid in the fish oil, can effectively reduce LDL-C in the blood, reduce neutral fat content, increase HDL-C, be universally recognized adjusting blood fat raw material;
(2) have the alpha-linolenic acid of high level in the linseed oil, alpha-linolenic acid can promote cholesterol to drain, suppress that endogenous cholesterol is synthetic, increasing high density lipoprotein, thereby reaches the effect that reduces blood fat.
The specific embodiment
A kind of fish oil linseed oil soft capsule, primary raw material comprises following component and weight portion content: fish oil 30-80, linseed oil 20-60, vitamin E 5-20.Wherein, fish oil is selected one or more in tunny fish oil or the cod oil for use, and the significant composition that this product is determined is EPA, DHA and a-leukotrienes, and EPA, DHA are the significant compositions of fish oil, and the a-leukotrienes is the significant composition of linseed oil.
During this product was raw materials used, EPA content was not less than 18wt% in the fish oil of selecting for use, and DHA content is not less than 12wt%.Linolenic acid content is 50wt% in the linseed oil.Below the raw material components that adopts is further elaborated, further specify it and can obtain the required technique effect that reaches of the application.
The active component that assistant lipid-lowering class health food is commonly used mainly contains (1) polysaccharide (2) protein, peptide class and amino acids (3) unsaturated fatty acids at present.(4) vitamins.(5) flavonoids.(6) Polyphenols etc.Unsaturated fatty acids wherein, because derive from raw-food material, taking in right amount has no side effect liked by the consumer, therefore selected polyunsaturated fatty acid class is health factor.Through screening, selected fish oil and linseed oil select vitamin E as oxidation resistant auxiliary material as the primary raw material of product.Screening process is as follows:
Polyunsaturated fatty acid mainly comprises linoleic acid, leukotrienes, arachidonic acid, eicosapentaenoic acid EPA, DHA DHA etc., and wherein the maximum of research are EPA, DHA.Dyerbery etc. are to Greenland Eskimos's epidemiology survey, Eskimos's cardiovascular disease incidence rate of normal edible fishes, blubber oil is low, though high heat, high cholesterol diet, the incidence of disease such as coronary heart disease, diabetes and case fatality rate approximately only are of the same age Danish 10%.Discover that the DHA that is rich in the fish oil that they eat, EPA have played key effect.The effect for reducing fat that studies show that the fish oil that contains DHA, EPA is one of its important activity, and China major region is landlocked, lacks polyunsaturated fatty acid DHA, EPA from fish oil in the meals, so the selected fish oil of my company is one of primary raw material of product.
In the common edible oil of China, what alpha-linolenic acid content was more is linseed oil, and per 100 grams contain alpha-linolenic acid can reach about 50 grams.Alpha-linolenic acid can the catalytic action by desaturase and carbochain prolongation enzyme change into EPA and DHA in human body, edible alpha-linolenic acid (18:3n-3, the precursor of the long carbochain unrighted acid of n-3 type) can reach identical effect with fish oil, linseed output height, gross output occupies the 4th of China's oil-bearing crops, and China's line cultivated area and linseed output occupy the second place of the world.Be only second to Canada.A large amount of high-quality omega-fatty acids source can be provided.Linseed oil big with respect to fish oil output, economic feasibility is higher.Therefore the selected linseed oil of product is cooked another raw material, is used with fish oil.
Fish oil and linseed oil all are easy to oxidation deterioration, therefore add the oxidation of antioxidant vitamin E antagonism primary raw material.Fish oil and linseed oil all contain polyunsaturated fatty acid with health role, do not find that compatibility has harmful effect, because of cholesterol in the fish oil and cetoleic acid content higher, unsuitable excessive use adds the problem that linseed oil can be avoided excessive use fish oil in the prescription, take linseed separately and can not reach very good effect, because the transformation ratio of alpha-linolenic acid is lower, the two is used, and it is little to have a dose, safety, the advantage that health-care effect is good.
Studies show that polyunsaturated fatty acid (PUFAs) mainly participates in lipometabolic some rate-limiting enzyme by influence and acceptor is regulated blood fat.Polyunsaturated fatty acid reduces the level that participates in fat metabolic enzyme HMG-CoA reductase, content receptors such as the ldl receptor that increase resistance cholesterol, triglycerides synthesize, peroxisome Proliferator-activated receptor, and can suppress glycolysis and the genetic transcription of fat generation enzyme, raise thereby suppress blood fat.
The research of fish oil effect for reducing fat:
For maximum DHA and the EPA of polyunsaturated fatty acid research, its lipopenicillinase mechanism can be summarized as: (1) increases the drainage of ight soil sterol at present; (2) aliphatic acid that changes lipoprotein is formed; (3) suppress the synthetic of VLDL VLDL and low-density lipoprotein LDL; (4) the degraded removing speed of promotion VLDL.There are a large amount of animals and clinical testing to prove, are rich in the health care of the fish oil tool reducing blood lipid of DHA and EPA.
The feed domestic deep sea fish oil of rat various dose such as Zhang Rongbiao, experimental period is 28d, and establishes negative control.Result of the test shows: compare with control rats, 0.67, the 1.33g/kgbw deep sea fish oil can make the serum TC value reduce (P＜0.05), 1.33g/kgbw deep sea fish oil can make the serum TG value reduce (P＜0.05), the HDL-C value raises (P＜0.05), illustrates that domestic deep sea fish oil has the health care of auxiliary antilipemic.
Eel olein (127.7 such as Dan Chunwen, 255.4 and 510.8mg/kg) feed high fat rat, continuous 5 weeks, 255.4 and the dosage of 510.8mg/kg significantly reduces serum total cholesterol (TC), triglycerides (TG) and low-density lipoprotein (LDL) level, the dosage effect of 127.7mg/kg is not remarkable.The reduced rate of 3 dosage TC be respectively 13.3%, 37.1% and the reduced rate of 48.7%, TG be 9.5%, 12.9% and the reduced rate of 25.2%, LDL be 5.1%, 47.4% and 62.2%.255.4 and the dosage group of 510.8mg/kg remarkable increasing high density lipoprotein (HDL) level also.3 dosage amounts are respectively 8.2%, 67.3% and 61.2% to the rate of rise of HDL.
Mclntosh feeds the fish oil 8 months (every animal 2ml/d) that is rich in EPA and DHA to rat, and serum TC decline 16.6%, TG descends 7.0%.Give too mouse hello 1ml fish oil every days such as Roshanai, in continuous 6 weeks, serum TC and TG level all significantly are lower than control group, and vegetable oil group and control group are similar, say that the effect of fish oil reducing blood lipid is better than vegetable oil.
Clinical test results proves that also the fish oil that contains EPA and DHA has the function of reducing blood lipid.Ceng Jun etc. research eel olein adopts hypogastric lipid-lowering pill medicine in contrast to the curative effect of hyperlipidemia lipopenicillinase clinically, observes the eel olein to 50 routine patient's blood fat and Immune Effects.The result: the obvious effective rate that T-CHOL (TC) and triglycerides (TG) fall in the eel olein is respectively 92.0% and 88.0%, and total effective rate is 98.0% and 96.0%; There is reduction effect very significantly the treatment back to TC, TG, low-density lipoprotein (LDL) and VLDL (VLDL), and HDL (HDL) is had remarkable rising effect; Eel olein tool effect for reducing blood fat significantly is described, and can strengthens body immunity that effect significantly is better than contrasting the medicine hypogastric lipid-lowering pill.
After Zhong Ning etc. had observed the oral fish oil of 30 routine hyperlipidemia patients, blood fat, apolipoprotein, blood were pulled the variation of indexs such as PAR, blood viscosity for a short time, inquired into the value of fish oil in clinical treatment.Serum triglyceride (TG) level significantly descended after fish oil was taken in result's demonstration. total effective rate 66.7%, average 37.1% (P＜0.01) T-CHOL (TC) level that descends reduces. total effective rate 53.3%, average 16.0% (P＜0.01) and the HDL-C (HDL-C) of descending, LDL-C (LDL-C), aPoA
1And B (apoA,, apoB) level does not have significant change, but HDL-C/TC, significant difference (being P＜0.05) before and after HDL2-C/HDLmC apoA1/apoB ratio is taken medicine.The back blood of taking medicine is pulled PAR, blood viscosity, fibrinogen content obviously descend (P＜0.05,0.01) for a short time.Result of study explanation fish oil preparation (EPA ten DHA840mg/d) can effectively be regulated blood lipid level, and is obvious to fall the TG effect.
The research of linseed oil effect for reducing fat:
Linseed oil is rich in the a-leukotrienes, and its a-linolenic acid content is up to about 50%, and the a-leukotrienes is a kind of essential fatty acid.Belong to omega-fatty acid.In human body, under the effect of enzyme, can be converted into other ω-3 long-chain unsaturated fatty acid EP and DHA, have multiple physiologically active and function, thereby be subjected to great attention and the high praise of food nutrition circle.
Lin Hua etc. feed with homemade linseed oil (basic, normal, high 3 kinds of dosage) and raised rat 32 days, observe the influence of its ratio (HDL-C/TC) to rat blood serum cholesterol (TC), triglycerides (TG), HDL-C (HDL-C), HDL-C and T-CHOL, LDL-C (LDL-C), apolipoprotein one B (Apo-B) and artery sclerosis index (AI), and compare with high lipid food group and basal feed group.The result. the TC of the basic, normal, high dosage group of linseed meal and LDL-C all significantly are lower than high lipid food group (P＜005); The TG of middle and high dosage group, Apo-B and AI significantly are lower than high lipid food group (P＜005), and HDL-C/TC, AI are significantly higher than high lipid food group (P＜0.05). and HDL-C does not then have significant difference (P＞0.05) with the high lipid food group.The effect that α one linolenic homemade linseed has good reduction blood fat is rich in prompting.
Huang Qingde etc. for being tried thing, study the linseed oil effect for reducing fat with homemade linseed oil.According to blood lipid level and with reference to body weight, be divided into 5 groups (10 every group at random.Male and female half and half).Feed respectively normal diet (negative control), high lipid food (positive control), low dosage linseed oil high lipid food (0.4g/kgbw), middle dosage linseed oil high lipid food (0.8g/kgbw), high dose linseed oil high lipid food (1.2g/kgbw).Feed is directly tried thing, animal ad lib and drinking-water.Each dosage linseed oil group is irritated rat and is fed.Schedule to last 28d, weigh weekly once, 28d adopts tail hematometry TC, TG, HDL-c in experiment.Test and put to death animal latter stage.And the calm situation of anatomic observation rat body fat.The result shows, each dosage linseed oil group and positive controls are relatively behind the 28d, serum total cholesterol TC falls and reaches 27.0%～35.1%, triglycerides descends 3.8%～28.6%, HDL-C raises 3.48～9.28mg/dl, and linseed oil is extremely remarkable to the blood fat regulating action.Even the linseed oil of low dosage raises to the cholesterol TC that is tried thing the obvious suppression effect is arranged, and have tangible dose-effect relationship to suppressing aspects such as TG rising, increase HDL-C concentration.
Yang Tiankui etc. are on zooperal basis, with from as contrast, utilize raw material and the prescription identical with zoopery, clinical effect to the alpha-linolenic acid reducing blood lipid has been done systematic research, experimental subjects is to suffer from outpatient's 54 examples of hyperlipidemia, 54.1 ± 9.7 years old age (mean+SD).Each clothes alpha-linolenic acid capsule and pill (0.5 gram/grain, 10% alpha-linolenic acid), dose is 4/time, 3 times/day, obeys altogether 84 days.Surveyed blood lipids index and serum fatty acid in 0 day, 42 days and 84 days respectively and form, serum 16:0 behind the absorption alpha-linolenic acid capsule and pill, 18:0 and 18:1n-9 level reduce (P＜0.01); Plasma triglyceride significantly reduces (P＜0.05); Cholesterol, HDL and LDL change not obvious; Go out, cruor time extending (P＜0.05).Experimental result shows that a linolenic absorption can stop the synthetic of aliphatic acid, sweet three esters and accelerate beta oxidation; Effect with triglyceride reducing.
Fish oil linseed oil preparation of soft capsule method may further comprise the steps:
(1) preparation content: take by weighing fish oil, linseed oil, vitamin E by prescription, mix then and stir the content that obtained mixing in 30-60 minute;
(2) make utricule: be the utricule raw material with gelatin, glycerine and pure water, glycerine and pure water are injected in the glue pot, be heated with stirring to 60～70 ℃, add gelatin again, continue to stir final vacuum deaeration in 20-30 minute, make obtaining utricule;
(3) preparation capsule: content and step (2) making of step (1) preparation are obtained utricule process pelleting, finalize the design, wash ball, drying, choose ball and packing step, wherein Ding Xing temperature is that temperature is 18-30 ℃, relative humidity is 30-60%, shaping time is 4h, adopt the ethanol of 95wt% to wash the ball processing, dry temperature is 20-35 ℃, and be 8h drying time, finally prepare the fish oil soft capsule, contain raw material 1000mg in every capsules.
The present invention is described in detail below in conjunction with specific embodiment.
Embodiment 1
A kind of fish oil linseed oil soft capsule, primary raw material comprises following component and weight portion content: fish oil 30, linseed oil 20, vitamin E 5.The fish oil of selecting for use is tunny fish oil, and wherein EPA content is not less than 18wt%, and DHA content is not less than 12wt%.Linolenic acid content is 50wt% in the linseed oil of selecting for use.
Fish oil linseed oil preparation of soft capsule method may further comprise the steps:
(1) preparation content: take by weighing fish oil, linseed oil, vitamin E by prescription, mix then and stir the content that obtained mixing in 30 minutes;
(2) make utricule: be the utricule raw material with gelatin, glycerine and pure water, glycerine and pure water are injected in the glue pot, be heated with stirring to 60 ℃, add gelatin again, continue to stir final vacuum deaeration in 20 minutes, make obtaining utricule;
(3) preparation capsule: content and step (2) making of step (1) preparation are obtained utricule process pelleting, finalize the design, wash ball, drying, choose ball and packing step, prepare every fish oil soft capsule that contains the 1000mg raw material, wherein Ding Xing temperature is 10 ℃, relative humidity is 30%, shaping time is 4h, adopt the ethanol of 95wt% to wash the ball processing, dry temperature is 30 ℃, and be 8h drying time.
Embodiment 2
A kind of fish oil linseed oil soft capsule, primary raw material comprises following component and weight portion content: fish oil 50, linseed oil 40, vitamin E 10.The fish oil of selecting for use is tunny fish oil, and wherein EPA content is not less than 18wt%, and DHA content is not less than 12wt%.Linolenic acid content is 50wt% in the linseed oil of selecting for use.
Fish oil linseed oil preparation of soft capsule method may further comprise the steps:
(1) preparation content: take by weighing fish oil, linseed oil, vitamin E by prescription, mix then and stir the content that obtained mixing in 40 minutes;
(2) make utricule: be the utricule raw material with gelatin, glycerine and pure water, glycerine and pure water are injected in the glue pot, be heated with stirring to 60 ℃, add gelatin again, continue to stir final vacuum deaeration in 30 minutes, make obtaining utricule;
(3) preparation capsule: content and step (2) making of step (1) preparation are obtained utricule process pelleting, finalize the design, wash ball, drying, choose ball and packing step, wherein Ding Xing temperature is that temperature is 30 ℃, relative humidity is 50%, shaping time is 4h, adopt the ethanol of 95wt% to wash the ball processing, dry temperature is 30 ℃, and be 8h drying time, finally prepare the fish oil soft capsule, contain raw material 1000mg in every capsules.
Embodiment 3
A kind of fish oil linseed oil soft capsule, primary raw material comprises following component and weight portion content: fish oil 80, linseed oil 60, vitamin E2 0.The fish oil of selecting for use is cod oil, and wherein EPA content is not less than 18wt%, and DHA content is not less than 12wt%.Linolenic acid content is 50wt% in the linseed oil of selecting for use.
Fish oil linseed oil preparation of soft capsule method may further comprise the steps:
(1) preparation content: take by weighing fish oil, linseed oil, vitamin E by prescription, mix then and stir the content that obtained mixing in 60 minutes;
(2) make utricule: be the utricule raw material with gelatin, glycerine and pure water, glycerine and pure water are injected in the glue pot, be heated with stirring to 70 ℃, add gelatin again, continue to stir final vacuum deaeration in 30 minutes, make obtaining utricule;
(3) preparation capsule: content and step (2) making of step (1) preparation are obtained utricule process pelleting, finalize the design, wash ball, drying, choose ball and packing step, wherein Ding Xing temperature is that temperature is 30 ℃, relative humidity is 60%, shaping time is 4h, adopt the ethanol of 95wt% to wash the ball processing, dry temperature is 35 ℃, and be 8h drying time, finally prepare the fish oil soft capsule, contain raw material 1000mg in every capsules.
Fish oil, linseed oil are foodstuff, belong to the non-toxic type material, therefore paid attention to by people.Spring sesame hall board fish oil linseed oil soft capsule has been rich in-3 serial polyunsaturated fatty acid-EPA, DHA and alpha-linolenic acid, and lot of experiments proves that it all has the effect of significant auxiliary antilipemic.Embodiment 2 is made the properties of product that obtain test, its result is as follows.
The influence of table 1 couple hyperlipemia rat TC, TG, HDL-C
As seen from the above table, give high lipid food after, relatively, serum TC, the TG of rat all are significantly increased before control group experiment back and the experiment, surperficial high blood lipid model is set up.1.0g/kg.bw reach the level that 3.0g/kg.bw all can obviously reduce high fat rat TC and TG, compare with high fat control group, significant difference is arranged.
The influence of table 2 pair hyperlipemia rat blood lipid level
| Dosage (g/kg.bw) | Number of animals (only) | TC(％) | TG(％) | HDL-C(mmol/L) |
| 0.5 | 10 | 7.22 | 1.13 | -0.05 |
| 1.0 | 10 | 11.68 | 13.21 | -0.01 |
| 3.0 | 10 | 11.00 | 18.87 | 0.03 |
As seen from the above table, after giving high lipid food, compare with high fat control group, the blood TC decline percentage of the basic, normal, high dosage group of this product rat is respectively 7.22%, 11.68%, 11.00%, serum TG decline percentage is respectively 1.13%, 13.21%, 18.87%, Serum HDL-C rise be respectively-0.05mmol/L ,-0.01mmol/L, 0.03mmol/L.
Above-mentioned experimental data shows that this product that gives the rat various dose can obviously reduce TC and the TG level of high fat rat, compares with high fat control group, and significant otherness is arranged.According to " health food check and assessment technique standard " criterion, this product has the function of auxiliary antilipemic.
Claims (10)
1. a fish oil linseed oil soft capsule is characterized in that, the primary raw material in this soft capsule comprises following component and weight portion content: fish oil 30-80, linseed oil 20-60, vitamin E 5-20.
2. a kind of fish oil linseed oil soft capsule according to claim 1 is characterized in that described fish oil is one or more in tunny fish oil or the cod oil.
3. a kind of fish oil linseed oil soft capsule according to claim 1 and 2 is characterized in that EPA content is not less than 18wt% in the described fish oil, and DHA content is not less than 12wt%.
4. a kind of fish oil linseed oil soft capsule according to claim 1 is characterized in that linolenic acid content is 50wt% in the described linseed oil.
5. as each described fish oil linseed oil preparation of soft capsule method among the claim 1-4, it is characterized in that this method may further comprise the steps:
(1) preparation content: take by weighing fish oil, linseed oil, vitamin E by prescription, mix then and stir the content that obtained mixing in 30-60 minute;
(2) make utricule: be the utricule raw material with gelatin, glycerine and pure water, glycerine and pure water are injected in the glue pot, be heated with stirring to 60～70 ℃, add gelatin again, continue to stir final vacuum deaeration in 20-30 minute, make obtaining utricule;
(3) preparation capsule: content and step (2) making of step (1) preparation are obtained utricule process pelleting, finalize the design, wash ball, drying, choose ball and packing step, prepare the fish oil soft capsule.
6. a kind of fish oil linseed oil preparation of soft capsule method according to claim 5 is characterized in that, the weight ratio of gelatin, glycerine, pure water is 10-20: 5-20: 1-10 in the step (2).
7. a kind of fish oil linseed oil preparation of soft capsule method according to claim 5 is characterized in that the temperature of the typing described in the step (3) is 18-30 ℃, and relative humidity is 30-60%, and shaping time is 4h.
8. a kind of fish oil linseed oil preparation of soft capsule method according to claim 5 is characterized in that, adopts the ethanol of 95wt% to wash the ball processing in the step (3).
9. a kind of fish oil linseed oil preparation of soft capsule method according to claim 5 is characterized in that the temperature of the drying described in the step (3) is 20-35 ℃, and be 8h drying time.
10. a kind of fish oil linseed oil preparation of soft capsule method according to claim 5 is characterized in that, every contains raw material 1000mg in the soft capsule that making obtains.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101169046A CN103190619A (en) | 2013-04-03 | 2013-04-03 | Fish oil and linseed oil soft capsules and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101169046A CN103190619A (en) | 2013-04-03 | 2013-04-03 | Fish oil and linseed oil soft capsules and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103190619A true CN103190619A (en) | 2013-07-10 |
Family
ID=48713585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013101169046A Pending CN103190619A (en) | 2013-04-03 | 2013-04-03 | Fish oil and linseed oil soft capsules and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103190619A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103461993A (en) * | 2013-08-02 | 2013-12-25 | 新疆天山骄子食品有限责任公司 | Linolenic acid capsule production process |
| CN103598587A (en) * | 2013-11-20 | 2014-02-26 | 山西振东制药股份有限公司 | Health-care food with blood fat reduction assistance effect and preparation method thereof |
| CN104739860A (en) * | 2015-01-27 | 2015-07-01 | 上海天龙生物科技有限公司 | Alpha-linolenic acid DHA capsule |
| CN105707568A (en) * | 2014-12-04 | 2016-06-29 | 兰州大学 | Alpha-linolenic acid soft capsule with function of auxiliarily lowering blood lipids and preparation method thereof |
| CN106038508A (en) * | 2016-06-17 | 2016-10-26 | 上海春芝堂生物制品有限公司 | Plant capsule shell material, soft capsules, and preparation method and application of plant capsule shell material and soft capsule |
| CN106136243A (en) * | 2016-08-26 | 2016-11-23 | 李仁宝 | A kind of Sargassum extract health care soft capsule |
| CN109259235A (en) * | 2018-08-31 | 2019-01-25 | 安徽济生元药业有限公司 | A kind of improvement eyesight promotes brain development cod liver oil soft capsule |
| CN112931702A (en) * | 2021-03-25 | 2021-06-11 | 孚豪国际生物科技(山东)有限公司 | Fish oil soft capsule used in animal breeding and preparation method thereof |
| CN113519847A (en) * | 2021-07-28 | 2021-10-22 | 宁波天皓生物科技有限公司 | Production process of DHA algae oil product |
| CN114424823A (en) * | 2022-01-20 | 2022-05-03 | 江苏海王健康生物科技有限公司 | A soft capsule containing natural extract for reducing blood lipid, and its preparation method |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101229369A (en) * | 2008-01-29 | 2008-07-30 | 哈尔滨圣源生物工程有限责任公司 | Antiatheroscloresis thrombolytic soft capsule and preparing method thereof |
| CN101697799A (en) * | 2009-09-14 | 2010-04-28 | 蔡晓东 | Deep-sea fish oil soft capsules |
| CN101961352A (en) * | 2010-10-27 | 2011-02-02 | 南通迈特生物工程有限公司 | Self-emulsified fish oil soft capsules without fishy smell |
| CN102871132A (en) * | 2012-11-05 | 2013-01-16 | 江苏江大源生态生物科技有限公司 | Health care soft capsule for strengthening immunity and preparation method thereof |
-
2013
- 2013-04-03 CN CN2013101169046A patent/CN103190619A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101229369A (en) * | 2008-01-29 | 2008-07-30 | 哈尔滨圣源生物工程有限责任公司 | Antiatheroscloresis thrombolytic soft capsule and preparing method thereof |
| CN101697799A (en) * | 2009-09-14 | 2010-04-28 | 蔡晓东 | Deep-sea fish oil soft capsules |
| CN101961352A (en) * | 2010-10-27 | 2011-02-02 | 南通迈特生物工程有限公司 | Self-emulsified fish oil soft capsules without fishy smell |
| CN102871132A (en) * | 2012-11-05 | 2013-01-16 | 江苏江大源生态生物科技有限公司 | Health care soft capsule for strengthening immunity and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 唐年初 等: "天然维生素E对鱼油抗氧化性影响的研究", 《粮食与食品工业》 * |
| 梦想: "《卓越系统》", 2 October 2012 * |
| 郭永利 等: "亚麻籽的保健功效和药用价值", 《中国麻业科学》 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103461993A (en) * | 2013-08-02 | 2013-12-25 | 新疆天山骄子食品有限责任公司 | Linolenic acid capsule production process |
| CN103598587A (en) * | 2013-11-20 | 2014-02-26 | 山西振东制药股份有限公司 | Health-care food with blood fat reduction assistance effect and preparation method thereof |
| CN105707568A (en) * | 2014-12-04 | 2016-06-29 | 兰州大学 | Alpha-linolenic acid soft capsule with function of auxiliarily lowering blood lipids and preparation method thereof |
| CN104739860A (en) * | 2015-01-27 | 2015-07-01 | 上海天龙生物科技有限公司 | Alpha-linolenic acid DHA capsule |
| CN106038508A (en) * | 2016-06-17 | 2016-10-26 | 上海春芝堂生物制品有限公司 | Plant capsule shell material, soft capsules, and preparation method and application of plant capsule shell material and soft capsule |
| CN106136243A (en) * | 2016-08-26 | 2016-11-23 | 李仁宝 | A kind of Sargassum extract health care soft capsule |
| CN109259235A (en) * | 2018-08-31 | 2019-01-25 | 安徽济生元药业有限公司 | A kind of improvement eyesight promotes brain development cod liver oil soft capsule |
| CN112931702A (en) * | 2021-03-25 | 2021-06-11 | 孚豪国际生物科技(山东)有限公司 | Fish oil soft capsule used in animal breeding and preparation method thereof |
| CN113519847A (en) * | 2021-07-28 | 2021-10-22 | 宁波天皓生物科技有限公司 | Production process of DHA algae oil product |
| CN114424823A (en) * | 2022-01-20 | 2022-05-03 | 江苏海王健康生物科技有限公司 | A soft capsule containing natural extract for reducing blood lipid, and its preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103190619A (en) | Fish oil and linseed oil soft capsules and preparation method thereof | |
| Martirosyan et al. | Amaranth oil application for coronary heart disease and hypertension | |
| TWI393536B (en) | Lipid-improving agent and composition containing lipid-improving agent | |
| JP5546087B2 (en) | Oral treatment or prevention agent for skin diseases | |
| CN101720822A (en) | Nutritional blend oil with balanced fatty acid component and active component for middle and old aged | |
| CN103444911A (en) | Medicinal and edible health care blending oil | |
| CN101473953A (en) | Fabricated food for cleaning blood and expelling toxin as well as method for processing the same and application | |
| CN102948483B (en) | Blood fat reducing milk powder and preparation method thereof | |
| CN101810226A (en) | Fatty acid component balanced children type nutrition blended oil containing multiple active ingredients | |
| CN103380826A (en) | Functional fat with cardiovascular and cerebrovascular disease risk factor prevention function and preparation method thereof | |
| CN101940239A (en) | Special blend oil for pregnant women and children for balancing fatty acid components and supplementing arachidonic acid and vitamin A | |
| CN101099562A (en) | Omega-3 unsaturated fatty acids appetizer oil and producing method and application thereof | |
| CN101849585A (en) | Functional nutrient plant blend oil and preparation method thereof | |
| CN109527579A (en) | A kind of application of surprise Asia seed oil product and preparation method thereof and the sub- seed oil product of the surprise | |
| JP2006306813A (en) | Mast cell increase inhibitor | |
| CN102090486B (en) | Method for preparing nutrient linseed oil tea | |
| CN1298647A (en) | Health-care oil for regulating blood fat | |
| CN110050847A (en) | A kind of high fat diet and fatty acid mixed edible plant blend oil | |
| CN1141934C (en) | Health-care oil for regulating blood fat | |
| CN106433949A (en) | Low-acid-value Yunnan pine seed oil, preparation method and application thereof | |
| CN101978950A (en) | Alpha-linolenic acid ester fat emulsion injection and preparation method thereof | |
| CN105707568A (en) | Alpha-linolenic acid soft capsule with function of auxiliarily lowering blood lipids and preparation method thereof | |
| CN1566297A (en) | Perilla oil and its preparation process and use | |
| CN109364202A (en) | A kind of composition and its preparation method and application | |
| JP6203320B2 (en) | Oral treatment or prevention agent for skin diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130710 |